

PAR/CS/NSE/2026-27/02

Date: 14/05/2026

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra


Subject: Outcome of the Board Meeting held on Thursday, 14th day of May, 2026 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref.: Symbol- PAR, ISIN: INE04LG01015

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on **Thursday, 14th day of May, 2026 at 3:30 P.M. at 333/1, G.I.D.C. Industrial Estate, Phase-II, Chitra, Bhavnagar – 364004** transacted the following businesses:

Item No.	Outcomes
1.	Pursuant to section 184(1) of the Companies Act, 2013, each director placed FORM MBP – 1 and board took note of respective particulars of each director about his/her concern or interest in any company or companies or bodies corporate, firms, or other association of individuals.
2.	Pursuant to section 164 (2) of the Companies Act, 2013, each director placed FORM DIR-8 and board took note that none of the directors are disqualified pursuant to section 164 (2).
3.	Board took note of declarations received under section 149(7) of the Companies act, 2013 from all the Independent Directors of the Company in compliance with section 149(6) of the Companies Act, 2013 & Regulation 16 (1)(b) of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 and other requirement under respective act and regulation.
4.	<p>After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record of Audited financial results for the quarter and year ended on March 31, 2026 along with statement of assets and liabilities, statement of profit & loss and cash flow statement and Auditor's Report with unmodified opinion thereon, issued by CA Miral Mehta, Partner of Sarupria Somani & Associates, Chartered Accountants, Statutory Auditor of the Company. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbbhai Savani, CEO & Director (DIN: 00198203) to sign the approved financial results. The financial results were duly reviewed by Audit Committee at its meeting.</p> <p>Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Certificate of correctness was placed before the Board Meeting.</p> <p>Compliance Certificate pursuant to Regulation 17(8) read with Part B of Schedule II of SEBI (LODR) Regulations, 2015) is also submitted by the CEO and CFO of the Company</p> <p>Further, declaration is given by CFO of the Company pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.</p> <p>(The above documents are attached as Annexure 1,2,3 &4 respectively.)</p>



5.	The Board considered and approved the drafts of advertisements to be published in newspapers regarding Audited Standalone Financial Results of the Company for quarter and year ended on 31 st March, 2026. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay or as available.
6.	Board received, considered and approved Annual Audited financial statement with Audit Report for F.Y. 2025-26 ended on March 31, 2026 and authorised Mr. Falgun Savani (DIN: 00198236), Chairman & Managing Director; Mr. Jignesh Savani (DIN: 00198203), Director & CEO; Chief Financial Officer and Company Secretary of the company to sign the financial statements of the company including Balance Sheet as at March 31, 2026 and Statement of Profit and Loss for the year ended March 31, 2026 together with the notes and accounting policies attached thereto and Cash Flow Statements for the year ended on March 31, 2026 on behalf of the board and to submit the same to the Auditors of the company for their report thereon.
7.	After the recommendation of Audit Committee, Board received, considered and approved Internal Audit Report on the basis of internal audit conducted by M/s. SIDDHPURA & CO, Chartered Accountants for F.Y. 2025-26 ended on March 31, 2026.
8.	The Board took note of Investor grievances report for the quarter ended March 31, 2026 and reviewed the SCORES platform of SEBI to solve the investor compliant till date.
9.	The Board took note and review the Integrated Corporate Governance Report of the Company for the quarter ended March 31, 2026.
10.	Board received, considered and approved Human Resource Annual Report for the F.Y 2025-26 as presented by the HR head of the Company to the management and recommended to formulate strategies to foster a workforce-oriented approach in the year ahead.
11.	The Board took note of Actuarial valuation report as per AS 15 under the defined benefit scheme of Gratuity Benefits for the financial year ended March 31, 2026 received from Kapadia & Kochrekar Actuaries & Consultant of Mr. Saurabh Kochrekar, Fellow of Institute of Actuaries of India (ID: 19005)
12.	The board took note that the company has paid 10% of basic salary as a Bonus with total amount Rs. 25.14 lakh to the employees of the Company in the month of April 2026 for the F.Y. 2025-26
13.	By considering the suggestion of audit committee, the board has considered, discussed, approved and authorized Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and/or Mr. Jignesh V. Savani, Director & CEO (DIN: 00198203) of the Company to make investment as and when required in the liquid fund, arbitrage fund, fix deposit, etc up to the limit of ₹.90.00/- Crore approved by the board, which is within the limit defined under section 186 of the Companies Act, 2013.
14.	The Board considered and took note of renewal of Banking facility without any revision in the existing limit of Rs. 161.00 Lakh with Kotak Mahindra Bank, approved by the board and authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbhai Savani, CEO & Director (DIN: 00198203) to provide required resolution to the Bank and be and are hereby authorized to do sign/digitally sign all such necessary forms, documents, papers, and to do all such acts, matters, deeds as may be required for the above mentioned purpose.
15.	The Board considered and authorized Mr. Jignesh V. Savani, Director & CEO (DIN: 00198203) of the Company to file E-Form DPT-3 for the financial year ended on March 31, 2026, E-Form MGT-14 and other required Forms with the Registrar of Companies.
16.	The Board considered and authorized Mr. Jignesh V. Savani, Director & CEO (DIN: 00198203) of the Company to file FLA Return.
17.	The Board reviewed all policies of the Company as per the applicable act ,rules, regulations, etc. found proper by the Board
18.	Board reviewed terms and Conditions of appointment of Independent Directors found proper by the Board
19.	Board reviewed the code of conduct of the company found proper by the Board.
With the permission and consent of the Chairman and all the board of directors of the Company, following other matter were considered and approved	
20.	After the recommendation of Audit Committee, the Board of Directors has discussed, decided and approved to sale of Motor Vehicle of Company at total of Rs. 1.50 Lakh approx. Further, The Board authorised any of the current directors to sign and execute all such necessary forms, documents, agreement, papers, and to do all such acts, matters, deeds as may be required time to time for the sale of the motor vehicles.



Although all the submission is made by integrated financial in XBRL format, this intimation shall also be considered as Integrated Filing (Financial) for quarter and year ended on 31st March, 2026 pursuant to Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 as follows:

**QUARTERLY INTEGRATED FILING (FINANCIAL)
FOR THE QUARTER ENDED MARCH 31, 2026**

PARTICULARS	DISCLOSURE
A. FINANCIAL RESULTS	Enclosed
B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.	Not Applicable Reason of Non-Applicability: As there is no any proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.
C. OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES	Not Applicable Reason of Non-Applicability: As there is no any outstanding default on loans and debt securities.
D. DISCLOSURE OF RELATED PARTY TRANSACTIONS	Submitted with Integrated Financial in XBRL format on the exchange
E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS	Auditor's Report with unmodified opinion thereon, issued by CA Miral Mehta, Partner of Sarupria Somani & Associates, Chartered Accountants. Further, declaration given by CFO of the Company pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith. Further, the same is submitted with Integrated Financial in XBRL format on the exchange

Further, with reference to our intimation dated 26th March, 2026 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will be opened after 48 hours of declaration of the attached financial result for Designated persons, Designated employees and their immediate relatives.

The Board Meeting was commenced at 3:30 PM and concluded at 6:16 PM.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

For PAR DRUGS AND CHEMICALS LIMITED

(Sanket B. Trivedi)

Company Secretary & Compliance Officer

Encl: As above





Sarupria Somani & Associates Chartered Accountants

Partner : CA Miral Bipinbhai Mehta
B.Com, FCA

CA Miral B. Mehta
602, Victoria Corporate,
Opp. Gulista Ground, Sony Show
Room Lane, Vadodariya Park,
Bhavnagar. Gujarat-364001
Mobile : 9909366366
Email : somanibvn@gmail.com

INDEPENDENT AUDITOR'S REPORT

(Auditor's Report on Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing
Obligation and Disclosure Requirements) Regulation, 2015)

TO
THE BOARD OF DIRECTORS OF
PAR DRUGS AND CHEMICALS LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of **PAR DRUGS AND CHEMICALS LIMITED** (the company) for the **quarter ended 31st March, 2026** and the year-to-date results for the period from **1st April, 2025 to 31st March, 2026**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the **net profit** and other comprehensive income and other financial information for the quarter ended **31st March, 2026** as well as the year-to-date results for the period from **1st April, 2025 to 31st March, 2026**.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these

Branches

Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • Gandhinagar
Rudrapur • Indore • Pune • Kolkata • Ghaziabad • Raipur • Shimla • Chandigarh

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Assessment of Going Concern and Impact of Regulatory Proceedings on Strategic Restructuring**Why the matter was considered to be one of the most significant matters in the audit**

During the previous financial year, the Company had proposed a strategic restructuring plan involving the slump sale/business transfer of its primary business undertaking to a related party. The said undertaking constituted a substantial portion of the Company's revenue-generating and operational activities.

During the current financial year, the Securities and Exchange Board of India ("SEBI") issued an Ex-Parte Interim Order followed by a Confirmatory Order restraining the implementation of the proposed Business Transfer Arrangement ("BTA"). The Company is evaluating the available legal remedies, including the option of challenging the said orders before the appropriate appellate authority. Based on legal advice obtained and management's assessment of the matter, the management believes that it has adequate grounds to support its position.

Considering the significance of the proposed transaction, the ongoing regulatory proceedings, and the dependence of future business operations and funding plans on the outcome of such proceedings, significant management judgement and assumptions were involved in assessing the Company's ability to continue as a going concern. Accordingly, this matter was considered to be one of the most significant matters in our audit.

How the matter was addressed in the audit

Our audit procedures in relation to the above matter included, among others:

- Reviewing the Ex-Parte Interim Order and Confirmatory Order issued by SEBI and examining the related legal and regulatory correspondence made available to us;
- Discussing with management the current status of the proceedings and understanding the possible legal remedies available to the Company, including the proposed course of action before the appropriate appellate authority;
- Assessing management's evaluation of the impact of the regulatory proceedings on the proposed restructuring and on the future business operations of the Company;

- Reviewing management's cash flow forecasts, funding arrangements and key assumptions considered in assessing the appropriateness of the going concern basis of accounting;
- Considering legal opinions, representations and explanations provided by management in relation to the ongoing regulatory proceedings; and
- Evaluating the adequacy and appropriateness of disclosures made in the financial statements relating to the regulatory proceedings, uncertainties associated with the proposed transaction and the Company's going concern assessment.

Based on the audit procedures performed and the information and explanations provided to us, we found management's assessment of the going concern assumption to be reasonable and the related disclosures in the financial statements to be adequate and appropriate.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year-to-date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

SARUPRIA SOMANI & ASSOCIATES
(Firm Registration No – 010674C)
CHARTERED ACCOUNTANTS



MIRAL MEHTA (Partner)

M.No.145361

Bhavnagar, 14th May, 2026

UDIN – 26145361ZYAAUO2067



To,
The Board of Directors
Par Drugs And Chemicals Limited

CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the quarter and year ended on 31st March, 2026 placed before the meeting do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited

Date: 14/05/2026

Place: Bhavnagar



(Mr. Jignesh V. Savani)
Chief Executive Officer



For Par Drugs And Chemicals Limited



(Mr. Chintan P. Chauhan)
Chief Financial Officer



COMPLIANCE CERTIFICATE

(Pursuant to Regulation 17(8) read with Part B of Schedule II of SEBI (LODR) Regulations, 2015)

To,
The Board of Directors
Par Drugs And Chemicals Limited

We, the undersigned, in our respective capacities as Chief Executive Officer and Chief Financial Officer of Par Drugs And Chemicals Limited ("the Company"), to the best of our knowledge and belief certify that:

- A. We have reviewed the financial statements and the cash flow statement for the year ended on 31st March, 2026 and based on our knowledge and belief, we state that:
1. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 2. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. We further state that to the best of our knowledge and belief, there are no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's Code of Conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.



D. We have indicated, based on our most recent evaluation, wherever applicable, to the Auditors and the Audit committee:

1. significant changes, if any, in internal control over financial reporting during the year;
2. significant changes, if any, in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
3. instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or any employee having significant role in the Company's internal control system over financial reporting.

For Par Drugs And Chemicals Limited

Date: 14/05/2026

Place: Bhavnagar




(Mr. Jignesh V. Savani)
Chief Executive Officer



For Par Drugs And Chemicals Limited



(Mr. Chintan P. Chauhan)
Chief Financial Officer



To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Date:14-05-2026

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

Symbol- PAR, ISIN: INE04LG01015

Dear Sir/Madam,

I, **Chintan P. Chauhan, Chief Financial Officer** of Par Drugs And Chemicals Limited hereby declare that the Statutory Auditors of the Company, M/s Sarupria Somani & Associates, Chartered Accountants, having FRN 010674C, Partnership Firm, having peer review certificate, has submitted an Audit Report **with unmodified opinion** on Audited Standalone Financial Results of the Company for the financial year ended March 31, 2026.

This declaration is given pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Kindly take on the record and acknowledge the receipt

Yours Faithfully

For PAR DRUGS AND CHEMICALS LIMITED



(Mr. Chintan P. Chauhan)
Chief Financial Officer

